CONMED (NYSE:CNMD) Releases FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 4.540-4.610 for the period, compared to the consensus earnings per share estimate of 4.540. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

A number of analysts have recently commented on CNMD shares. Weiss Ratings upgraded CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. BMO Capital Markets assumed coverage on CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective for the company. Wells Fargo & Company increased their price objective on CONMED from $46.00 to $49.00 and gave the stock an “equal weight” rating in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CONMED presently has a consensus rating of “Reduce” and a consensus price target of $44.00.

CONMED Trading Down 3.3%

CONMED stock opened at $44.21 on Friday. The firm has a 50-day moving average of $47.06 and a 200-day moving average of $41.45. CONMED has a one year low of $31.44 and a one year high of $53.66. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.49 and a quick ratio of 0.69. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 18.27, a P/E/G ratio of 2.07 and a beta of 0.94.

CONMED (NYSE:CNMD) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.04. CONMED had a return on equity of 13.93% and a net margin of 5.36%. The company had revenue of $335.56 million during the quarter, compared to analysts’ expectations of $336.28 million. During the same quarter last year, the company earned $1.08 EPS. CONMED’s revenue for the quarter was down .7% compared to the same quarter last year. On average, equities analysts expect that CONMED will post 4.58 earnings per share for the current fiscal year.

CONMED News Summary

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED raised its fiscal 2026 EPS outlook to $4.54-$4.61, with the midpoint above the $4.54 analyst consensus. The company maintained revenue guidance of approximately $1.4 billion, in line with expectations. CONMED Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Third-quarter adjusted earnings of $1.04 per share exceeded the $1.00 consensus estimate. JPMorgan raised its price target from $45 to $50, while Wells Fargo increased its target from $46 to $49, suggesting analysts see additional upside. CONMED Q3 Earnings Top Estimates
• Neutral Sentiment: Both JPMorgan and Wells Fargo retained neutral-style ratings—“neutral” and “equal weight”—despite their higher targets. This indicates improved valuation expectations but no strong bullish conviction.
• Negative Sentiment: Quarterly revenue of approximately $335.6 million was essentially in line with estimates but declined about 0.7% year over year. EPS also fell from $1.08 in the prior-year quarter, signaling limited near-term operating momentum. CONMED Q3 Profit Rises and Updates 2026 Guidance

About CONMED

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.